Abstract 2281
Background
TM is a useful tool that improves access to medical care for rural residents. However, factors that correlate with a positive TM experience are not well known. The study aims to determine TM experience in cancer patients and physicians, and to explore clinical and socio-economic factors (CSF) that are associated with a positive TM experience in patients.
Methods
In this cross-sectional study cancer patients on active treatment and physicians in the province of Saskatchewan, Canada completed a paper-based comprised of 32 items or an electronic survey of 18 items, respectively. Six point likert score was used. Logistic regression analysis was done to assess correlation between self-reported CSF and a positive TM experience. We present here preliminary results.
Results
Overall 25 physicians and 165 patients responded to the survey over a period of three months. Among physicians 69% were in practice for ≥10 yrs with M:F of 1.7:1. 94% were confident in their TM assessment, 58% felt that TM improve clinical efficiency, and 74% felt that doctor-patient rapport was unimpaired with TM. Of 165 patients with median age of 67 years (IQR 59-75) and M:F of 1.06:1, 60% were ≥65 yrs, 70% were married, and 82% had a dependent family member. 94% were born in Canada, 77% were Caucasian, 29% were working and 35% had annual income of < 40K. 67% had solid tumor, 46% reported having a curable cancer, 31% had surgery, 27% had radiation, and 62% had chemotherapy. 61% used TM first time. 90% felt that their needs were met, 91% felt that TM improved their quality of care, and 91% had a good experience. Overall, 83% patients vs. 45% physicians preferred TM to in-person clinic visit (P = 0.005). Only univariate analysis only age ≥65 was strongly associated with a positive TM experience, odd ratio 4.1 (1.2-13.8), p = 0.02. No other CSF including marital status, income, working status, dependent family member, and cancer type were significantly correlated with a positive TM experience.
Conclusions
This study supports a higher rate of positive TM experience in cancer patients and physicians. However, high preference of TM was noted among patient compared with physicians. Among various variables examined only older age was associated with a positive TM experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shahid Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract